EXPERIENCE OF APPLYING MONOCLONAL ANTIBODIES TO TNF α — ADALIMUMAB — IN A CHILD WITH JUVENILE IDIOPATHIC ARTHRITIS
https://doi.org/10.15690/pf.v10i4.770
Abstract
The article offers successful application of a preparation of human monoclonal antibodies to tumor necrosis factor (TNF) α – adalimumab – in the setting of a severe course of juvenile idiopathic arthritis characterized by inefficiency of the standard antirheumatic therapy and secondary resistance to chimeric antibodies to TNF α. Adalimumab treatment secured overcoming of the secondary infliximab inefficiency, rapid disease activity decrease, peripheral joints’ function recovery and the patient’s functional activity increase in a short space of time. The drug averted the patient’s steadily progressing incapacitation and induced the clinical-laboratory disease remission development.
About the Authors
E. I. Alexeeva
Scientific Center of Children’s Health, Moscow
The First Sechenov Moscow State Medical University
Russian Federation
PhD, Professor, head of the rheumatology department at the Scientific Center of Children’s Health
Russian Federation
PhD, Professor, head of the rheumatology department at the Scientific Center of Children’s Health
K. B. Isaeva
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
R. V. Denisova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
T. V. Sleptsova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
S. I. Valiyeva
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
T. M. Bzarova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
E. V. Mitenko
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
A. M. Chomakhidze
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
References
1. Furst D. E., Schiff M. H., Fleischmann R. M., Strand V., Birbara C. A., Сompagnone D. et al. Adalimumab, a fully human antitumor necrosis factor _ monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 2003; 30: 2563–2571.
2. Weinblatt M. E., Keystone E. C., Furst D. E., Moreland L. W., Weisman M. H., Birbara C. A. et al. Adalimumab, a fully human antitumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate the ARMADA trial [published erratum appears in Arthritis Rheum 2003,48 855]. Arthritis Rheum. 2003; 48: 35–45.
3. Keystone E. C., Kavanaugh A. F., Sharp J. T., Tannenbaum H., Hua Y., Teoh L. S. et al. Radiographic, clinical, and functional outcomes of treatment with Adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy a randomized, placebocontrolled, 52-week trial. Arthritis Rheum. 2004; 50: 1400–1411.
4. Van de Putte L. B., Atkins C., Malaise M., Sany J., Russell A. S., van Riel P. L. et al. Efficacy and safety of Adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 2004; 63: 508–516.
5. Mease P. J., Gladman D. D., Ritchhn C. T., Ruderman E. M., Steinfeld S. D., Choy E. H. et al. For the ADEPT Study Group
6. Adalimumab for the treatment of patients with moderately to severely active psoratic arthritis results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52: 3279–3289.
7. Alekseeva E. I., Sleptsova T. V., Valieva S. I., Denisova R. V., Bzarova T. M., Lisitsyn A. O., Gudkova E. Yu., Chomakhidze A. M., Isaeva K. B., Grigor'eva A. A., Lomakina O. L. Voprosy sovremennoi pediatrii = Current pediatrics. 2009; 8 (4): 42–50.
8. Van der Bijl A. E., Breedveld F. C. et al. Adalimumab (humira) is effective in treating patients with rheumatoid arthritis who previously failed infliximab treatment. Ann Rheum. Dis. 2005; 64 (Suppl. III): 428.
9. Alekseeva E. I., Grigor'eva A. A., Denisova R. V. Voprosy sovremennoi pediatrii = Current pediatrics. 2009; 8 (6): 42–47.
10. Alekseeva E. I., Lisitsyn A. O., Karagulyan N. A. Voprosy sovremennoi pediatrii = Current pediatrics. 2009; 8 (3): 88–94.
11. Lipsky P. E., van der Heijde D. M. F.M., St Clair E. W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 2000; 343: 1594–1602.
12. Feldman M., Brennan P., Maini R. Role of cytokines in rheumatoid arthritis. Annu Rev. Immunol. 1996; 14: 397–440.
13. Beutler B. The rote of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (Suppl. 57): 16–21.
14. Aikawa N. E., De Carvalho J. F., Silva C. A. et al. Immunogenicity of anti-TNF_ agents in autoimmune diseases. Clinic. Rev. Allerg. Immunol. 2010; 38 (2–3): 82–89.
15. Haibel H., Rudwaleit M., Listing J. et al. Efficacy of Adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008 Jul; 58 (7): 1981–1991.
16. Wijbrandts C. A., Klaasen R., Dijkgraaf M. G. еt al. Bone mineral density in rheumatoid arthritis patients 1 year after Adalimumab therapy: arrest of bone loss? Ann Rheum Dis. ARD Online First, published on April 13, 2008 as 10.1136/ard. 2008.091611.
17. Kimel M., Cifaldi M., Chen N., Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol. 2008 Feb; 35 (2): 206–15.
18. Luchikhina E. L., Karateev D. E., Nasonov E. L. Nauchno-prakticheskaya revmatologiya = Research and practical rheumatology. 2008; 5: 59–63.
19. Lovell D., Ruperto N., Reiff A., Jung Lawrence K., Higgins G., Kone-Paut I., Jones Olcay Y., McIlraith Melissa J., Andhivarothai N., Kupper H., Giannini Edward H., Peterson T., Martini A. Long-Term Efficacy and Safety of Adalimumab for up to 6 Years in Patients with Juvenile Idiopathic Arthritis. Abstract presented at: 75th Annual scientific meeting of the American College of Rheumatology (ACR) and the 46th Annual meeting of the Association of Rheumatology Health Professionals (ARHP); 11/5/2011 Chicago, IL; USA. 2011. Abstract MIS (7190791).
20. Schett G., Coates L. C., Zoe R. Ash, Finzel S., Conaghan P. G. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Research & Therapy. 2011; 13 (Suppl. 1): S4.
21. Vazquez-Сobian L. B., Flynn T., Lehman T. J. A. Adalimumab therapy for childhood uveitis. J. Pediatr. 2006; 149: 572–575.
22. Tynjala P., Kotaniemi K., Lindahl P. et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008 Mar; 47 (3): 339–44. Epub 2008 Jan 31.
23. Biester S., Deuter C., Michels H. et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007 Mar; 91 (3): 274–276.
24. Heiligenhaus A., Horneff G., Greiner K. et al. Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood. Klin. Monatsbl. Augenheilkd. 2007 Jun; 224 (6): 526–31.
25. Alekseeva E. I., Valieva S. I., Denisova R. V., Bzarova T. M. Voprosy sovremennoi pediatrii = Current pediatrics. 2008; 7 (5): 51–56.
26. Alekseeva E.I., Mitenko E.V., Valieva S.I., Bzarova T.M., Denisova R.V., Isaeva K.B., Sleptsova T.V., Chomakhidze A.M. Voprosy sovremennoi pediatrii = Current pediatrics. 2012; 11: 82–90.
27. Namazova-Baranova L.S. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9 (4): 15–24.
Review
For citations:
Alexeeva E.I., Isaeva K.B., Denisova R.V., Sleptsova T.V., Valiyeva S.I., Bzarova T.M., Mitenko E.V., Chomakhidze A.M. EXPERIENCE OF APPLYING MONOCLONAL ANTIBODIES TO TNF α — ADALIMUMAB — IN A CHILD WITH JUVENILE IDIOPATHIC ARTHRITIS. Pediatric pharmacology. 2013;10(4):149-153. https://doi.org/10.15690/pf.v10i4.770
Views:
682
Email this article 